THE US FDA has approved
Levemir (insulin detemir [rDNA
origin] injection) for use in children
aged 2-5 years with type 1 diabetes.
The FDA approval now makes
Levemir the first and only basal
insulin analog in the US for use in
this young patient group.
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 23 May 12
Pharmacy Daily is Australia's favourite online publication dedicated to the pharmacy industry. The publication launched in March 2007 and is distributed every day by email to pharmacists across the country. MORE